Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES

ERR1524203 E-MTAB-4917:MEM001.MEM.131023.HiSeq2000.FCB.lane8.R Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERX1595165 202 0 Application Read Forward 1 1 Application Read Reverse 102 ENA-FIRST-PUBLIC 2017-05-04 ENA-LAST-UPDATE 2018-11-16 ERR1524204 E-MTAB-4917:MEM002.MEM.131023.HiSeq2000.FCB.lane8.R Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERX1595166 202 0 Application Read Forward 1 1 Application Read Reverse 102 ENA-FIRST-PUBLIC 2017-05-04 ENA-LAST-UPDATE 2018-11-16 ERR1524205 E-MTAB-4917:MEM003.MEM.131023.HiSeq2000.FCB.lane8.R Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERX1595167 202 0 Application Read Forward 1 1 Application Read Reverse 102 ENA-FIRST-PUBLIC 2017-05-04 ENA-LAST-UPDATE 2018-11-16 ERR1524206 E-MTAB-4917:MEM004.MEM.131023.HiSeq2000.FCB.lane8.R Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERX1595168 202 0 Application Read Forward 1 1 Application Read Reverse 102 ENA-FIRST-PUBLIC 2017-05-04 ENA-LAST-UPDATE 2018-11-16 ERR1524207 E-MTAB-4917:MEM005.MEM.131107.HiSeq2000.FCB.lane7.R Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERX1595169 202 0 Application Read Forward 1 1 Application Read Reverse 102 ENA-FIRST-PUBLIC 2017-05-04 ENA-LAST-UPDATE 2018-11-16 ERR1524208 E-MTAB-4917:MEM006.MEM.131107.HiSeq2000.FCB.lane7.R Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERX1595170 202 0 Application Read Forward 1 1 Application Read Reverse 102 ENA-FIRST-PUBLIC 2017-05-04 ENA-LAST-UPDATE 2018-11-16 ERR1524209 E-MTAB-4917:MEM007.MEM.131107.HiSeq2000.FCB.lane7.R Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERX1595171 202 0 Application Read Forward 1 1 Application Read Reverse 102 ENA-FIRST-PUBLIC 2017-05-04 ENA-LAST-UPDATE 2019-01-24 ERR1524210 E-MTAB-4917:MEM008.MEM.131107.HiSeq2000.FCB.lane7.R Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERX1595172 202 0 Application Read Forward 1 1 Application Read Reverse 102 ENA-FIRST-PUBLIC 2017-05-04 ENA-LAST-UPDATE 2019-01-24 ERR1524211 E-MTAB-4917:MEM009.MEM.131107.HiSeq2000.FCB.lane8.R Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERX1595173 202 0 Application Read Forward 1 1 Application Read Reverse 102 ENA-FIRST-PUBLIC 2017-05-04 ENA-LAST-UPDATE 2018-11-16 ERR1524212 E-MTAB-4917:MEM010.MEM.131107.HiSeq2000.FCB.lane8.R Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERX1595174 202 0 Application Read Forward 1 1 Application Read Reverse 102 ENA-FIRST-PUBLIC 2017-05-04 ENA-LAST-UPDATE 2018-11-16 ERR1524213 E-MTAB-4917:eMEM011_T1.MEM.140627.HiSeq2000.FCA.lane2.R Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERX1595175 202 0 Application Read Forward 1 1 Application Read Reverse 102 ENA-FIRST-PUBLIC 2017-05-04 ENA-LAST-UPDATE 2018-11-16 ERR1524214 E-MTAB-4917:eMEM011_N1.MEM.140627.HiSeq2000.FCA.lane3.R Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERX1595176 202 0 Application Read Forward 1 1 Application Read Reverse 102 ENA-FIRST-PUBLIC 2017-05-04 ENA-LAST-UPDATE 2018-11-16 ERR1524215 E-MTAB-4917:eMEM012_T1.MEM.140627.HiSeq2000.FCA.lane2.R Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERX1595177 202 0 Application Read Forward 1 1 Application Read Reverse 102 ENA-FIRST-PUBLIC 2017-05-04 ENA-LAST-UPDATE 2018-11-16 ERR1524216 E-MTAB-4917:eMEM012_N1.MEM.140627.HiSeq2000.FCA.lane1.R Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERX1595178 202 0 Application Read Forward 1 1 Application Read Reverse 102 ENA-FIRST-PUBLIC 2017-05-04 ENA-LAST-UPDATE 2018-11-16 ERR1524217 E-MTAB-4917:eMEM012_N1.MEM.140807.HiSeq2000.FCB.lane3.R Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERX1595178 202 0 Application Read Forward 1 1 Application Read Reverse 102 ENA-FIRST-PUBLIC 2017-05-04 ENA-LAST-UPDATE 2018-11-16 ERR1524218 E-MTAB-4917:eMEM013_N1.MEM.140627.HiSeq2000.FCA.lane1.R Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERX1595179 202 0 Application Read Forward 1 1 Application Read Reverse 102 ENA-FIRST-PUBLIC 2017-05-04 ENA-LAST-UPDATE 2018-11-16 ERR1524219 E-MTAB-4917:eMEM015_T1.MEM.140627.HiSeq2000.FCA.lane1.R Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERX1595180 202 0 Application Read Forward 1 1 Application Read Reverse 102 ENA-FIRST-PUBLIC 2017-05-04 ENA-LAST-UPDATE 2018-11-16 ERR1524220 E-MTAB-4917:eMEM015_T1.MEM.140807.HiSeq2000.FCB.lane3.R Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERX1595180 202 0 Application Read Forward 1 1 Application Read Reverse 102 ENA-FIRST-PUBLIC 2017-05-04 ENA-LAST-UPDATE 2018-11-16 ERR1524221 E-MTAB-4917:eMEM016_T1.MEM.140627.HiSeq2000.FCA.lane1.R Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERX1595181 202 0 Application Read Forward 1 1 Application Read Reverse 102 ENA-FIRST-PUBLIC 2017-05-04 ENA-LAST-UPDATE 2019-01-24 ERR1524222 E-MTAB-4917:eMEM017_T1.MEM.140627.HiSeq2000.FCA.lane2.R Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERX1595182 202 0 Application Read Forward 1 1 Application Read Reverse 102 ENA-FIRST-PUBLIC 2017-05-04 ENA-LAST-UPDATE 2018-11-16 ERR1524223 E-MTAB-4917:eMEM018_T1.MEM.140627.HiSeq2000.FCA.lane1.R Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERX1595183 202 0 Application Read Forward 1 1 Application Read Reverse 102 ENA-FIRST-PUBLIC 2017-05-04 ENA-LAST-UPDATE 2018-11-16 ERR1524224 E-MTAB-4917:eMEM018_T1.MEM.140807.HiSeq2000.FCB.lane3.R Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERX1595183 202 0 Application Read Forward 1 1 Application Read Reverse 102 ENA-FIRST-PUBLIC 2017-05-04 ENA-LAST-UPDATE 2018-11-16 ERR1524225 E-MTAB-4917:eMEM019_T1.MEM.140627.HiSeq2000.FCA.lane3.R Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERX1595184 202 0 Application Read Forward 1 1 Application Read Reverse 102 ENA-FIRST-PUBLIC 2017-05-04 ENA-LAST-UPDATE 2018-11-16